Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
From BioCentury This Week · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut (https://www.biocentury.com/article/659752) by Parabilis, the largest IPO in the sector’s history. The analysts also discuss the Biosecure Act (https://www.biocentury.com/article/659709) and U.S. policy toward China; the cachexia pipeline (https://www.biocentury.com/article/659459); and BioCentury’s updated Innovation Distillery (https://bciq.biocentury.com/innovation-distillery/insights).
View full story: https://www.biocentury.com/article/659773
#BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech
00:36 - Innovation Distillery 03:56 - Biotech IPOs 10:13 - Biosecure Act, WuXi AppTec 16:03 - Cachexia Pipeline 22:03 - Ouster for RFK Jr.?
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)